PKIB

PKIB is an endogenous inhibitor of the cAMP-dependent protein kinase A catalytic subunit (PKA-C) that functions through a pseudosubstrate domain and a leucine-rich nuclear export signal to regulate PKA activity and subcellular localization (PMID:10880337, PMID:19483721). PKIB directly binds PKA-C to promote its nuclear translocation and stimulates Akt Ser473 phosphorylation, linking cAMP/PKA signaling to PI3K/Akt pathway activation in cancer cells, while also inhibiting PKA-mediated phosphorylation of specific substrates such as HSP27 (PMID:19483721, PMID:27325557, PMID:40593489). PKIB additionally interacts with the G-protein-coupled zinc receptor GPR39, from which it is released upon zinc stimulation to inhibit PKA, forming a negative-feedback loop that couples receptor signaling to PKA suppression (PMID:24869658). Transcription of PKIB is induced by HIF1 under chronic hyperglycemia to impair pancreatic beta cell function through PKA inhibition, and by AR, GR, and MYCN in distinct cancer contexts to drive proliferation and therapy resistance (PMID:25704817, PMID:31289138, PMID:38030378, PMID:40593489).

1. 2000 Medium

   Cloning of PKIB established it as a third member of the PKI gene family, resolving whether additional PKA inhibitor genes existed beyond PKIA and PKIG and revealing that PKIB encodes both a pseudosubstrate inhibitory domain and a nuclear export signal.

   Evidence cDNA cloning, Northern blot, and radiation hybrid mapping in human tissues

   PMID:10880337

   Open questions at the time

   • No direct demonstration of PKA inhibitory activity by recombinant PKIB protein
   • Nuclear export function of the NES motif was inferred from sequence homology, not tested experimentally
   • Tissue-specific functional relevance remained uncharacterized
2. 2009 High

   Demonstration that PKIB physically binds PKA-C and is required for PKA-C nuclear translocation resolved how PKIB controls PKA localization; the finding that PKIB enhances PKA-C-mediated Akt Ser473 phosphorylation in vitro revealed an unexpected pro-oncogenic link between PKA inhibition and Akt activation.

   Evidence Co-immunoprecipitation, siRNA knockdown, overexpression, in vitro kinase assay, and nuclear fractionation in prostate cancer cells

   PMID:19483721

   Open questions at the time

   • Whether PKIB promotes Akt phosphorylation by directly altering PKA-C substrate specificity or by an indirect mechanism was not resolved
   • In vivo validation of the PKIB–Akt axis was lacking
   • Structural basis of the PKIB–PKA-C interaction was not determined
3. 2014 High

   Identification of GPR39 as a PKIB-binding partner established a receptor-level mechanism: PKIB is sequestered at GPR39 and released by zinc to inhibit PKA, creating a ligand-gated negative-feedback loop on cAMP signaling.

   Evidence Yeast-two-hybrid screen, co-expression functional assays, pseudosubstrate domain mutagenesis, and SRE-reporter assay

   PMID:24869658

   Open questions at the time

   • Endogenous PKIB–GPR39 interaction was not confirmed by co-IP from native tissue
   • Physiological tissue context for this feedback loop was not established
   • Whether other GPCRs similarly sequester PKI family members was unknown
4. 2015 High

   Genetic deletion of PKIB improved glucose tolerance in obese mice, establishing PKIB as a physiologically relevant PKA inhibitor in pancreatic islets and placing it in a HIF1→PKIB→PKA pathway that mediates hyperglycemia-induced beta cell dysfunction.

   Evidence PKIB knockout mouse model, oral glucose tolerance tests, islet functional assays, HIF1-dependent gene induction

   PMID:25704817

   Open questions at the time

   • Whether PKIB deletion rescues beta cell mass versus function was not dissected
   • Relative contributions of PKIA and PKIG in islets were not addressed
   • Downstream PKA substrates mediating the islet phenotype were not identified
5. 2016 Medium

   Epistasis experiments in NSCLC cells showed that PKIB's pro-proliferative and pro-invasive effects depend on PI3K/Akt pathway activation, generalizing the PKIB–Akt connection beyond prostate cancer.

   Evidence PI3K inhibitor epistasis, siRNA knockdown, overexpression, proliferation, and invasion assays in NSCLC cells

   PMID:27325557

   Open questions at the time

   • The direct molecular step linking PKIB/PKA-C to PI3K/Akt activation was not defined
   • In vivo NSCLC tumor model validation was absent
   • Single-lab finding without independent replication
6. 2019 Medium

   ChIP analysis demonstrated that the androgen receptor directly binds the PKIB promoter in aromatase inhibitor-resistant breast cancer, establishing the first defined transcription factor that directly drives PKIB expression in a therapy-resistance context.

   Evidence ChIP assay, RNA-seq, hormone manipulation in AI-resistant breast cancer cells

   PMID:31289138

   Open questions at the time

   • Functional consequence of AR-driven PKIB on PKA activity in breast cancer was not measured
   • Whether PKIB is required for AI resistance was not tested by genetic depletion
   • Single-lab observation
7. 2020 Medium

   PKIB knockdown in trophoblasts reduced pAkt and downstream MMP2/MMP9, impairing migration, invasion, and tube formation, extending the PKIB–Akt axis to placental biology and suggesting a role in preeclampsia pathogenesis.

   Evidence siRNA knockdown, real-time cell analysis, tube formation and spheroid sprouting assays, western blot in HTR8/SVneo cells

   PMID:32676926

   Open questions at the time

   • No patient-derived tissue validation of PKIB downregulation in preeclampsia
   • Whether PKA catalytic activity is involved or the effect is PKA-independent was not tested
   • Single cell line study
8. 2024 Medium

   In CRPC, glucocorticoid receptor directly upregulates PKIB after AR inhibition, leading to nuclear PKA-C accumulation and CREB phosphorylation; pharmacologic GR antagonism reduced PKIB and delayed CRPC progression, identifying PKIB as a GR-dependent resistance mediator.

   Evidence Gene expression analysis, xenograft mouse model with SGRM treatment, PKA-C nuclear localization and pCREB western blot

   PMID:38030378

   Open questions at the time

   • Whether PKIB is sufficient (not just necessary) for GR-driven CRPC resistance was not shown
   • The paradox of PKIB as a PKA inhibitor yet promoter of nuclear PKA-C and pCREB was not mechanistically resolved
   • Single-lab finding
9. 2025 Medium

   PKIB was shown to suppress PKA-mediated HSP27 phosphorylation at serines 15, 78, and 82, identifying the first specific PKA substrate regulated by PKIB; MYCN was found to directly bind the PKIB promoter, adding a third oncogenic transcription factor driving PKIB expression.

   Evidence Western blot for HSP27 phospho-sites, promoter binding assay for MYCN, proliferation/migration/invasion assays, in vivo bladder cancer model

   PMID:40593489

   Open questions at the time

   • Whether HSP27 dephosphorylation is the primary effector of PKIB-driven bladder cancer phenotypes was not tested
   • Single-lab finding without independent confirmation of MYCN–PKIB regulation
   • Structural basis for PKIB selectivity toward HSP27 phosphorylation versus other PKA substrates was not addressed

• The mechanism by which PKIB, nominally a PKA inhibitor, simultaneously promotes nuclear PKA-C translocation and Akt Ser473 phosphorylation remains unresolved; whether these reflect direct allosteric effects on PKA-C, scaffolding functions, or context-dependent conformational switching is unknown.
• No structural or biophysical data on the PKIB–PKA-C complex exist
• The paradox of PKA inhibition versus nuclear PKA-C accumulation has not been mechanistically reconciled
• Whether PKIB functions differently from PKIA and PKIG in any biological context remains untested by direct comparison